C
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CELZCIK 0001187953NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthBiological Products, (No Diagnostic Substances)NevadaFY ends Dec 31
Period
FY 2025
Revenue
$6.0K
Net Income
$-6.00M
Total Assets
—
Equity
—
Shares Out
3.70M
Op. Cash Flow
$-5.86M
Business
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company developing regenerative cell therapies across immunotherapy, endocrinology, urology, neurology, and orthopedics. The company offers multiple proprietary platforms including ImmCelz™ (reprogrammed immune cells), AlloStem™ (allogenic perinatal cell line), StemSpine® (autologous stem cell procedure for lower back pain), and programs targeting Type 1 Diabetes, premature ovarian failure, and erectile dysfunction. Products are in clinical phases or marketed through physician offices, with development supported by partnerships including Greenstone Biosciences for induced pluripotent stem cell advancement.
Summary from 10-K filed 2026-03-20
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 6,000 | 11,000 | 9,000 | 88,600 | 87,754 | |
| Cost of revenues | 2,194 | 4,400 | 3,600 | 28,491 | 47,949 | |
| Gross profit | 3,806 | 6,600 | 5,400 | 60,109 | 39,805 | |
| Research and development | 2 | 2 | 2 | 6 | 109,180 | |
| Selling, general and administrative | 4 | 3 | 4 | 4 | 3 | |
| Amortization of patent costs | 123,327 | 110,452 | 94,584 | 92,084 | 92,084 | |
| TOTAL EXPENSES | 6 | 6 | 6 | 10 | 3 | |
| Operating loss | −6 | −6 | −6 | −10 | −3 | |
| Interest income | 147,806 | 250,380 | 333,558 | 100,328 | — | |
| Total other income (expense) | 147,806 | 250,380 | 333,558 | 100,328 | 22 | |
| LOSS BEFORE PROVISION FOR INCOME TAXES | −6 | −5 | −5 | −10 | 19 | |
| Provision for income taxes | 0 | 0 | — | — | — | |
| NET LOSS | −6 | −5 | — | — | — | |
| Net income attributable to non-controlling interest | 0 | 0 | — | — | — | |
| NET LOSS ATTRIBUTABLE TO CMTH | −6 | −5 | −5 | −10 | 19 | |
| NET LOSS PER SHARE - BASIC AND DILUTED | −2.52 | −3.71 | −3.76 | −0.93 | 5.61 | |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED | 2 | 1 | 1 | 11 | 3 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 7 | 6 | 3 | 8 | — | |
| Inventory | 0 | 2,194 | 6,594 | 10,194 | 10,866 | |
| Note receivable, net of premium | 52,084 | 0 | — | — | — | |
| Prepaids and other current assets | 138,804 | 192,707 | 277,246 | 338,120 | 0 | |
| Total Current Assets | 7 | 6 | 10 | 19 | 11 | |
| Other assets | 3,281 | 3,281 | 3,281 | 3,281 | 3,281 | |
| Licenses, net of amortization | 407,230 | 530,559 | 441,011 | 435,595 | 527,679 | |
| TOTAL ASSETS | 8 | 7 | 11 | 19 | 11 | |
| Accounts payable | 270,686 | 273,530 | 317,280 | 3 | 761,862 | |
| Accrued expenses | 0 | 39,920 | 39,920 | 39,920 | 24,385 | |
| Advances from related party | 14,194 | 14,194 | 14,194 | 14,194 | — | |
| Total Current Liabilities | 284,880 | 327,644 | 371,394 | 3 | 1 | |
| TOTAL LIABILITIES | 284,880 | 327,644 | 371,394 | 3 | 1 | |
| Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2025 and 2024 | 0 | 0 | 0 | — | 0 | |
| Common stock, $0.001 par value, 25,000,000 shares authorized; 3,701,668 and 1,748,428 issued and 3,696,668 and 1,748,428 outstanding at December 31, 2025 and 2024, respectively | 3,144 | 1,749 | 1,431 | 1,407 | 6,339 | |
| Additional paid-in capital | 78 | 71 | 70 | 70 | 54 | |
| Accumulated deficit | −71 | −65 | −59 | −54 | −44 | |
| Treasury stock, at cost, 5,000 and 0 shares as of December 31, 2025 and 2024, respectively | −10,000 | 0 | −270,952 | — | — | |
| TOTAL STOCKHOLDERS' EQUITY | 8 | 6 | 10 | 16 | 10 | |
| Non-controlling interest | 10,000 | 0 | — | — | — | |
| TOTAL EQUITY ATTRIBUTABLE TO CMTH | 8 | 6 | 10 | — | — | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 8 | 7 | 11 | 19 | 11 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 3,485 | 36,648 | 36,648 | 68,746 | 595,380 | |
| Amortization of note receivable premium | −1,584 | 0 | — | — | — | |
| Inventory | 2,194 | 4,400 | 3,600 | 672 | −10,866 | |
| Prepaids and other current assets | 53,903 | 84,539 | 108,202 | −338,120 | 0 | |
| Accounts payable | −2,842 | −43,850 | −3 | 3 | 410,963 | |
| Accrued expenses | −39,920 | 0 | 0 | 15,535 | 20,635 | |
| Advances from related party | 0 | 0 | — | — | — | |
| Net cash used in operating activities | −6 | −5 | −8 | −8 | −2 | |
| Issuance of note receivable | −50,500 | 0 | — | — | — | |
| Redemptions of investments | 0 | 7 | — | — | — | |
| Payment of patent purchase obligation - related party | 0 | −200,000 | −100,000 | — | — | |
| Net cash provided by (used in) investing activities | −50,500 | 6 | 3 | −10 | 0 | |
| Contribution from minority member | 10,000 | 0 | — | — | — | |
| Purchase of treasury stock | −10,000 | −174,964 | −270,952 | 0 | — | |
| Proceeds from sale of common stock and warrants, net of issuance costs | 7 | 2 | 0 | 15 | 15 | |
| Proceeds from sale of Series B preferred stock | 0 | 100 | 0 | — | — | |
| Net cash provided by financing activities | 7 | 1 | −270,952 | 15 | 13 | |
| NET CHANGE IN CASH | 1 | 2 | — | — | — | |
| Cash payments for interest | 0 | 0 | 0 | 0 | 9,186 | |
| Cash payments for income taxes | 0 | 0 | 0 | 0 | 0 | |
| Cancellation of Series B preferred stock within accounts payable | 0 | 100 | 0 | — | — | |
| Cancellation of treasury stock | 0 | 445,916 | 0 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s CIK number?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s SEC CIK number is 0001187953 (1187953). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s SEC filings?
All of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.